WO2024130119A3 - Synbiotic compositions for short chain fatty acid production - Google Patents

Synbiotic compositions for short chain fatty acid production Download PDF

Info

Publication number
WO2024130119A3
WO2024130119A3 PCT/US2023/084290 US2023084290W WO2024130119A3 WO 2024130119 A3 WO2024130119 A3 WO 2024130119A3 US 2023084290 W US2023084290 W US 2023084290W WO 2024130119 A3 WO2024130119 A3 WO 2024130119A3
Authority
WO
WIPO (PCT)
Prior art keywords
chain fatty
short chain
fatty acid
acid production
prebiotic
Prior art date
Application number
PCT/US2023/084290
Other languages
French (fr)
Other versions
WO2024130119A2 (en
Inventor
Gregory Mckenzie
Julie E. Button
Abigail REENS
Casey COSETTA
Aislinn ROWAN-NASH
Original Assignee
Prolacta Bioscience, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolacta Bioscience, Inc. filed Critical Prolacta Bioscience, Inc.
Publication of WO2024130119A2 publication Critical patent/WO2024130119A2/en
Publication of WO2024130119A3 publication Critical patent/WO2024130119A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided herein are compositions, methods, strategies, kits, and articles of manufacture that are useful, inter alia, in the treatment or prevention of diseases, disorders, or conditions that may be associated with inflammation, infection, allergy, immune dysfunction, or dysbiosis of the intestinal microbiome. In some aspects, the invention provides a synergistic combination of a prebiotic, e.g., a mixture of human milk oligosaccharides, and probiotic strains of bacteria, such as one or more strains capable of internalizing and consuming the prebiotic, e.g., Bifidobacterium longum subsp. infantis, and one or more strains capable of producing short chain fatty acids such as propionate, e.g., Veillonella sp.
PCT/US2023/084290 2022-12-16 2023-12-15 Synbiotic compositions for short chain fatty acid production WO2024130119A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263387807P 2022-12-16 2022-12-16
US63/387,807 2022-12-16
US202363490283P 2023-03-15 2023-03-15
US63/490,283 2023-03-15

Publications (2)

Publication Number Publication Date
WO2024130119A2 WO2024130119A2 (en) 2024-06-20
WO2024130119A3 true WO2024130119A3 (en) 2024-07-18

Family

ID=89663231

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/084290 WO2024130119A2 (en) 2022-12-16 2023-12-15 Synbiotic compositions for short chain fatty acid production

Country Status (1)

Country Link
WO (1) WO2024130119A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010057022A1 (en) * 2008-11-14 2010-05-20 Genomatica, Inc. Microorganisms for the production of methyl ethyl ketone and 2-butanol
WO2016049932A1 (en) * 2014-09-30 2016-04-07 Bgi Shenzhen Co., Limited Biomarkers for obesity related diseases
WO2021108728A1 (en) * 2019-11-27 2021-06-03 Seres Therapeutics, Inc. Designed bacterial compositions and uses thereof
WO2022036225A1 (en) * 2020-08-14 2022-02-17 Prolacta Bioscience, Inc. Human milk oligosaccharide compositions for use with bacteriotherapies

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20020182243A1 (en) 2001-05-14 2002-12-05 Medo Elena Maria Method of producing nutritional products from human milk tissue and compositions thereof
CA2623483A1 (en) 2005-09-20 2007-03-29 Prolacta Bioscience, Inc. A method for testing milk
ES2634613T3 (en) 2006-08-30 2017-09-28 Prolacta Bioscience, Inc. Methods of obtaining sterile milk and compositions thereof
US9084434B2 (en) 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
CA2706722C (en) 2006-11-29 2016-01-12 Prolacta Bioscience, Inc. Human milk compositions and methods of making and using same
WO2010065652A1 (en) 2008-12-02 2010-06-10 Prolacta Bioscience, Inc. Human milk permeate compositions and methods of making and using same
ES2439507T3 (en) 2011-01-20 2014-01-23 Jennewein Biotechnologie Gmbh Novel fucosyltransferases and their applications
US20140235850A1 (en) 2011-09-30 2014-08-21 Glycom A/S Synthesis of hmo core structures
WO2013139344A1 (en) 2012-03-20 2013-09-26 Glycom A/S Synthesis of the trisaccharide 3-o-fucosyllactose and intermediates thereof
WO2013182206A1 (en) 2012-06-08 2013-12-12 Glycom A/S Method for producing oligosaccharides and oligosaccharide glycosides by fermentation
US20150182549A1 (en) 2012-06-22 2015-07-02 Glycom A/S Method for enzymatic glycosylation of oligosaccharides from mammalian animal milk
US20150183816A1 (en) 2012-06-22 2015-07-02 Glycom A/S Modified galactooligosaccharides
WO2014135167A1 (en) 2013-03-08 2014-09-12 Glycom A/S Purification of oligosaccaharides by reversible derivatization
GB201306687D0 (en) 2013-04-12 2013-05-29 Glycom As Synthesis of sialylated/fucosylated oligosaccharides
GB201306689D0 (en) 2013-04-12 2013-05-29 Glycom As Synthesis of sialylated/fucosylated human milk oligosaccharides
US10364449B2 (en) 2013-09-06 2019-07-30 Glycom A/S Fermentative production of oligosaccharides
DK2845905T3 (en) 2013-09-10 2021-06-14 Chr Hansen Hmo Gmbh Preparation of oligosaccharides
EP2857410A1 (en) 2013-10-04 2015-04-08 Jennewein Biotechnologie GmbH Process for purification of 2´-fucosyllactose using simulated moving bed chromatography
ES2701163T3 (en) 2014-01-20 2019-02-21 Jennewein Biotechnologie Gmbh Procedure for the efficient purification of neutral human milk oligosaccharides (HMOs) from microbial fermentation
ES2715010T3 (en) 2014-03-31 2019-05-31 Jennewein Biotechnologie Gmbh Total oligosaccharide fermentation
CN106460024B (en) 2014-06-27 2021-10-01 格礼卡姆股份公司 Preparation of oligosaccharides
EP3141610A1 (en) 2015-09-12 2017-03-15 Jennewein Biotechnologie GmbH Production of human milk oligosaccharides in microbial hosts with engineered import / export
EP3390652A4 (en) 2015-12-18 2019-06-12 Glycom A/S Fermentative production of oligosaccharides
CN109843073A (en) 2016-09-19 2019-06-04 普罗莱克塔生物科学公司 Purified human milk oligosaccharides composition
PL3315610T3 (en) 2016-10-29 2021-06-14 Jennewein Biotechnologie Gmbh Process for the production of fucosylated oligosaccharides
EP3425052A1 (en) 2017-07-07 2019-01-09 Jennewein Biotechnologie GmbH Fucosyltransferases and their use in producing fucosylated oligosaccharides
EP3450443A1 (en) 2017-08-29 2019-03-06 Jennewein Biotechnologie GmbH Process for purifying sialylated oligosaccharides
MX2022002949A (en) 2019-09-24 2022-04-06 Prolacta Bioscience Inc Compositions and methods for treatment of inflammatory and immune diseases.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010057022A1 (en) * 2008-11-14 2010-05-20 Genomatica, Inc. Microorganisms for the production of methyl ethyl ketone and 2-butanol
WO2016049932A1 (en) * 2014-09-30 2016-04-07 Bgi Shenzhen Co., Limited Biomarkers for obesity related diseases
WO2021108728A1 (en) * 2019-11-27 2021-06-03 Seres Therapeutics, Inc. Designed bacterial compositions and uses thereof
WO2022036225A1 (en) * 2020-08-14 2022-02-17 Prolacta Bioscience, Inc. Human milk oligosaccharide compositions for use with bacteriotherapies

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Veillonella dispar strain NCTC11831 genome assembly, chromosome: 1 - Nucleotide - NCBI", VEILLONELLA DISPAR STRAIN NCTC11831 GENOME ASSEMBLY, CHROMOSOME: 1, 19 December 2018 (2018-12-19), pages 1 - 5, XP093143061, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/nuccore/LR134375.1> [retrieved on 20240319] *
LIU YAFEI ET AL: "Substrate Use Prioritization by a Coculture of Five Species of Gut Bacteria Fed Mixtures of Arabinoxylan, Xyloglucan, [beta]-Glucan, and Pectin", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 1 November 2019 (2019-11-01), United States, pages e01905 - e01919, XP093142662, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6952225/pdf/AEM.01905-19.pdf> [retrieved on 20240319], DOI: 10.1128/AEM.01905-19 *
LOUIS PETRA ET AL: "The gut microbiota, bacterial metabolites and colorectal cancer", NATURE REVIEWS MICROBIOLOGY, vol. 12, no. 10, 8 September 2014 (2014-09-08), GB, pages 661 - 672, XP093040336, ISSN: 1740-1526, Retrieved from the Internet <URL:https://www.nature.com/articles/nrmicro3344> DOI: 10.1038/nrmicro3344 *
MASHIMA IZUMI ET AL: "Comparative Pan-Genome Analysis of Oral Veillonella Species", MICROORGANISMS, vol. 9, no. 8, 20 August 2021 (2021-08-20), pages 1775, XP093142826, ISSN: 2076-2607, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400620/pdf/microorganisms-09-01775.pdf> DOI: 10.3390/microorganisms9081775 *
P DELIA ET AL: "Use of probiotics for prevention of radiation-induced diarrhea", WORLD J GASTROENTEROL, vol. 14, no. 6, 14 February 2007 (2007-02-14), pages 912 - 915, XP055592130, DOI: 10.3748/wjg.v13.i6.912 *
SCHEIMAN JONATHAN ET AL: "Meta-omics analysis of elite athletes identifies a performance-enhancing microbe that functions via lactate metabolism", NATURE MEDICINE, NATURE PUBLISHING GROUP US, NEW YORK, vol. 25, no. 7, 24 June 2019 (2019-06-24), pages 1104 - 1109, XP036928348, ISSN: 1078-8956, [retrieved on 20190624], DOI: 10.1038/S41591-019-0485-4 *
SULIGOJ TANJA ET AL: "Effects of Human Milk Oligosaccharides on the Adult Gut Microbiota and Barrier Function", NUTRIENTS, vol. 12, no. 9, 13 September 2020 (2020-09-13), CH, pages 2808, XP093142605, ISSN: 2072-6643, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551690/pdf/nutrients-12-02808.pdf> DOI: 10.3390/nu12092808 *

Also Published As

Publication number Publication date
WO2024130119A2 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
MX2022002949A (en) Compositions and methods for treatment of inflammatory and immune diseases.
Iqbal et al. Probiotics and their beneficial effects against various diseases.
Ghadimi et al. Effects of probiotic bacteria and their genomic DNA on TH1/TH2-cytokine production by peripheral blood mononuclear cells (PBMCs) of healthy and allergic subjects
Malaguarnera et al. Probiotics in the gastrointestinal diseases of the elderly
JP5832297B2 (en) Compositions comprising probiotic and prebiotic components and inorganic salts with lactoferrin
Mego et al. Probiotic bacteria in cancer patients undergoing chemotherapy and radiation therapy
RU2560440C2 (en) Lactobacillus plantarum strain as hypocholesterolemic agents (versions) and application thereof
Ale et al. Lactobacillus fermentum: Could EPS production ability be responsible for functional properties?
EP4424319A3 (en) Novel lactobacillus having various functions, and use thereof
Jonganurakkun et al. Pediococcus pentosaceus NB-17 for probiotic use
RU2019110063A (en) PROBIOTIC BACTERIA STRAINS RELATING TO THE GENUS Bifidobacterium, AND PROBIOTIC EXTRACTS OF THESE CELLS (PCE) WITH IMMUNOSTIMULATING PROPERTIES
PT2236598E (en) Microorganisms for improving the health of individuals with disorders related to gluten ingestion
BR112022004432A2 (en) Bacterial strains, their compositions and their use for the treatment of gastrointestinal disorders
Fangous et al. Lactobacilli intra-tracheal administration protects from Pseudomonas aeruginosa pulmonary infection in mice–a proof of concept
Roy et al. Functional food: probiotic as health booster
WO2019098810A3 (en) Novel lactic acid bacteria and use thereof
Bolla et al. Kefir-isolated bacteria and yeasts inhibit Shigella flexneri invasion and modulate pro-inflammatory response on intestinal epithelial cells
MX2023008227A (en) Synbiotic treatment regimens.
KR101847154B1 (en) Health supplementary food containing lactic acid bacteria
Sarmurzina et al. Characterization of Probiotic Strains of Lactobacillus Candidates for Development of Synbiotic Product for Kazakh Population.
WO2024130119A3 (en) Synbiotic compositions for short chain fatty acid production
MX2024000566A (en) Probiotic composition for the treatment of increased intestinal permeability.
WO2022234511A3 (en) Compositions comprising bacterial strains for treatment of diseases associated with alterations in glucose metabolism
Zárate et al. Inhibition of enteropathogens adhesion to human enterocyte-like HT-29 cells by a dairy strain of Propionibacterium acidipropionici
US12029768B2 (en) Probiotics useful for eradicating helicobacter pylori infection